CD274 and neoplasm: Considering the evidence derived from the different studies of chemotherapy plus neoadjuvant immunotherapy on programmed death-1 ligand 1 (PD-L1) levels as a predictor of tumor response to immunotherapy, it was concluded that this biomarker should always be evaluated in the biopsy performed at diagnosis in patients with locally advanced disease to have predictive information on treatment response [15, 17, 18, 20–22, 34].